title: Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase.
abstract: Several chemoattractants can regulate the recruitment of eosinophils to sites of inflammation, but the hierarchy among them is unknown. We observed here that eosinophil chemotaxis towards eotaxin or 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) was amplified up to sixfold in the presence of prostaglandin (PG) D2. This effect was only seen in eosinophils, and not in neutrophils or basophils. Pretreatment with the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) antagonist ramatroban prevented the PGD2 enhancement of eosinophil migrations. In contrast, eotaxin or 5-oxo-ETE inhibited the migration of eosinophils towards PGD2. 5-oxo-ETE enhanced the chemotaxis to eotaxin, while eotaxin had no effect on 5-oxo-ETE-induced migration. 5-oxo-ETE induced the phosphorylation of p38 mitogen-activated protein kinase, and inhibition of p38 mitogen-activated protein kinase by SB-202190 converted the effect of 5-oxo-ETE on the chemotaxis to PGD2 from inhibition to enhancement. The presence of blood or plasma markedly decreased the sensitivity of eosinophils to eotaxin or 5-oxo-ETE, while responses to PGD2 were unaltered. In conclusion, PGD2 might be an initial chemoattractant, since it maintains its potency in the circulation and augments the responsiveness of eosinophils to other chemoattractants. In contrast, eotaxin seems to be an end-point chemoattractant, since it has reduced efficacy in blood and is capable of down-modulating eosinophil responsiveness to other chemoattractants.
authors.affiliation: Institute of Experimental and Clinical Pharmacology, Medical University Graz, Graz, Austria.
authors.forename: Petra
authors.initials: P
authors.lastname: Schratl
authors.forename: Eva M
authors.initials: EM
authors.lastname: Sturm
authors.forename: Julia F
authors.initials: JF
authors.lastname: Royer
authors.forename: Gunter J
authors.initials: GJ
authors.lastname: Sturm
authors.forename: Irmgard T
authors.initials: IT
authors.lastname: Lippe
authors.forename: Bernhard A
authors.initials: BA
authors.lastname: Peskar
authors.forename: Akos
authors.initials: A
authors.lastname: Heinemann
mesh_terms: D001095:Arachidonic Acids / Q000276:immunology / Q000378:metabolism; D002227:Carbazoles / Q000494:pharmacology; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000276:immunology / Q000378:metabolism; D002631:Chemotactic Factors, Eosinophil / Q000276:immunology* / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000276:immunology* / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism*
chemical_list: D001095:Arachidonic Acids; C515456:CCL11 protein, human; D002227:Carbazoles; D054413:Chemokine CCL11; D019742:Chemokines, CC; D002631:Chemotactic Factors, Eosinophil; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; C080828:5-oxo-6,8,11,14-eicosatetraenoic acid; D048051:p38 Mitogen-Activated Protein Kinases; C063119:ramatroban; D015230:Prostaglandin D2